Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized double-blind study of BAT1806 versus tocilizumab in rheumatoid arthritis
CTR20190174Phase 3Completed
- Sponsor
- BeiGene
- Start
- Feb 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of omalizumab biosimilar SYN008 in rheumatoid arthritis (RA), sponsored by BeiGene. Started Feb 2019; status: completed.
02
Drugs
omalizumab biosimilar SYN008
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on CTR20190174.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20190174.